The IL1B Knockout 143B Polyclonal Cells product comprises a CRISPR/Cas9-edited polyclonal population of human 143B osteosarcoma cells harboring a targeted disruption of the IL1B gene. This loss-of-function model eliminates expression of interleukin-1 beta (IL-1??), a master pro-inflammatory cytokine, providing a genetically defined tool for interrogating IL-1??-dependent signaling networks in a bone cancer background. The polyclonal nature of the knockout pool reflects a heterogeneous collection of edited alleles, enabling robust population-level functional studies without clonal selection artifacts.
The parental 143B cell line is a well-characterized human osteosarcoma model derived from a KRAS-mutant bone tumor. These cells exhibit aggressive growth properties, high tumorigenic potential, and a mesenchymal phenotype, making them particularly suitable for investigating the interplay between oncogenic signaling and the inflammatory microenvironment. The KRAS mutation drives constitutive MAPK pathway activation, which synergizes with IL-1??-induced signaling to amplify tumor-promoting inflammation.
IL1B encodes IL-1??, a potent cytokine that orchestrates inflammatory and immune responses through binding to the IL-1 receptor complex (IL1R1/IL1RAP). This engagement recruits the adaptors MYD88, IRAK1, IRAK4, and TRAF6, leading to activation of the canonical NF-??B pathway via the IKK complex, which phosphorylates and degrades I??B?? (NFKBIA), thereby releasing p65 (RELA) to transcriptionally regulate target genes. Concurrently, IL-1?? stimulates MAPK cascades, including ERK1/2 (MAPK3/MAPK1), JNK (MAPK8), and p38 (MAPK14), culminating in the activation of transcription factors such as AP-1 (JUN, FOS) and ATF2. Downstream effectors include pro-inflammatory cytokines (IL6, IL8), cyclooxygenase-2 (PTGS2/COX2), matrix metalloproteinases (MMP1, MMP3, MMP9), adhesion molecules (ICAM1, VCAM1), and chemokines (CCL2, CXCL1), many of which are directly implicated in tumor invasion and metastasis. IL-1?? production itself is induced by Toll-like receptor ligands, TNF, and NLRP3 inflammasome-mediated caspase-1 processing.
In the context of 143B osteosarcoma cells, IL-1?? knockout attenuates a critical node linking inflammatory stimuli to cancer progression. This model enables dissection of IL-1?¡?s role in promoting an immunosuppressive tumor microenvironment, enhancing osteoclast recruitment, and facilitating bone metastasis??a hallmark of osteosarcoma pathology. By uncoupling IL-1?? from its downstream effectors, researchers can assess how loss of this cytokine modulates KRAS-driven signaling, matrix remodeling, and immune cell crosstalk.
Typical applications include mechanistic studies of inflammation-mediated tumor growth, high-content screening of IL-1?? pathway inhibitors, and validation of therapeutic targets in bone malignancy. Investigators can employ a suite of assays: western blotting and ELISA to confirm IL-1?? depletion, RT-qPCR for downstream gene expression, NF-??B luciferase reporters for pathway activity, and migration/invasion assays to assess metastatic capacity. Co-culture systems with immune cells permit evaluation of paracrine effects, while phospho-signaling analysis and RNA-sequencing reveal global network rewiring. For further technical details or to discuss custom applications, please contact Ascent Research.
